|Last Price$1.47||Day Change (%)-2.65%|
|Open Price$1.50||Day Change ($)-0.04|
|Day Range1.40–1.51||52-Week Range0.41–1.59|
As of Tue 6/30/2015 5:00:00 PM | USD
GTx GTXI announced Thursday that the Data Safety Monitoring Board has given it the green light to proceed with Phase III trials for Acapodene. We're leaving our fair value estimate unchanged as we had anticipated a smooth interim review. In our opinion, Acapodene's potential exposure to generic ...
Computex 2015: Microsoft showcases new Windows 10 devices from partners and broadens the ecosystem opportunity
GTx adds a European partner.
We are raising GTx's fair value on recent positive Phase II trial results for Ostarine.